Key facts
- Contrea’s last known valuation is $6.7M (Jun 2023).
- It has raised $8.9M; the latest was Later Stage VC ($6.0M) in Jan 2026.
- Notable investors include Global Brain, Mizuho Capital, East Ventures, Nippon Venture Capital, DBJ Capital — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Contrea
- ·The full record, as it builds
Funding rounds
No funding rounds for Contrea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Contrea
Developer of a medical software designed to provide an informed outlet support system that utilizes videos. The company's software offers content of informed consent, including a lecture that conveys prerequisite knowledge, such as an outline of illness, treatment methods and complications, as well as support for patient feelings, decision-making and questions and answers, enabling patients to watch videos issued by doctors as many times as they like from any place and time.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Employees
- 50
- Website
- contrea.jp/
- Ownership
- Privately Held (backing)
Contrea doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Contrea shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Contrea in its N-PORT filings yet. We sweep new filings monthly.